Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
1. Nuvalent aligns with FDA for zidesamtinib NDA submission by Q3 2025. 2. Zidesamtinib shows 44% response rate in TKI pre-treated NSCLC patients. 3. Durability of response is promising, with significant intracranial responses. 4. Nuvalent advances clinical trials for both zidesamtinib and neladalkib. 5. Zidesamtinib offers potential as a best-in-class treatment option.